Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.66 |
| ▸ | FAAH | O00519 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18122074 | 1.00 | NOD1 (0.66) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL21578572 | 0.98 | NOD1 (0.63) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL16644868 | 0.95 | NOD1 (0.60) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL22184249 | 0.92 | SLC6A5 (0.67) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL12749410 | 0.92 | SLC6A5 (0.67) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL23447033 | 0.91 | NOD1 (0.56) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL18637452 | 0.88 | DNM1 (0.57) | NOD1FAAHKMT2AMEN1MAPK1 | |
| SCHEMBL13214013 | 0.88 | NOD1 (0.61) | NOD1FAAH | |
| SCHEMBL13214006 | 0.88 | NOD1 (0.61) | NOD1FAAH | |
| SCHEMBL7520670 | 0.88 | NOD1 (0.64) | NOD1FAAHKMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096646-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130210709-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210709-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2010053550-A2 | CXCR4 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210709-A1 | CXCR4 Receptor Compounds | CXCR4, CXCL12, SDF4 | NOD1 613/4885FAAH 4015/4885KMT2A 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.